Liu Y.-L.Miser J.S.WEN-MING HSU2020-03-052020-03-0520140929-6646https://www.scopus.com/inward/record.uri?eid=2-s2.0-84918515454&doi=10.1016%2fj.jfma.2014.11.001&partnerID=40&md5=52452c0571c35fb411c8db16d5715569https://scholars.lib.ntu.edu.tw/handle/123456789/469991[SDGs]SDG3isotretinoin; MYCN protein, human; nuclear protein; oncoprotein; autologous stem cell transplantation; cancer radiotherapy; disease course; follow up; high risk population; human; induction chemotherapy; nerve cell differentiation; neuroblastoma; palliative therapy; Short Survey; Taiwan; adolescent; cancer staging; child; gene amplification; gene dosage; genetics; infant; medical research; neuroblastoma; newborn; pathology; preschool child; prognosis; risk assessment; young adult; Adolescent; Biomedical Research; Child; Child, Preschool; Gene Amplification; Gene Dosage; Humans; Infant; Infant, Newborn; Neoplasm Staging; Neuroblastoma; Nuclear Proteins; Oncogene Proteins; Prognosis; Risk Assessment; Young Adultjournal article10.1016/j.jfma.2014.11.001254999512-s2.0-84918515454